Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant

Stock Information for Elite Pharmaceuticals, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.